Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)

Who May Qualify: - Pathologically confirmed diagnosis of renal cell carcinoma of any histology - Age ≥ 18 years. - You should be able to carry out daily activities with 0 level of ability (ECOG 0)-2. - Imaging suggests the presence of distant metastases, with no more than 5 metastatic lesions according to RECIST 1.1 criteria and MDA standards. - The patient has received local therapy to primary site, including surgery, stereotactic radiotherapy, or ablation. - The patient has received no more than 2 lines of systemic therapy. - No significant impairment of major organ function: Hemoglobin (HB) ≥ 80 g/L Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L Platelets (PLT) ≥ 75 × 10⁹/L Serum total bilirubin ≤ 1.5 × ULN Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN Prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN Who Should NOT Join This Trial: - Presence of intracranial metastases. - Target lesions have previously received high-dose irradiation with . - Target lesions are unsuitable for radiation therapy judged by treating radiation oncologist (e.g., lesions invading the gastrointestinal tract or penetrating the bronchus). - Uncontrollable metastatic pleural effusion or ascites. - Presence of other malignancies that have not been cured. - History of significant psychiatric disorders that impede understanding of willing to sign a consent form and compliance with the study protocol. - Presence of other serious illnesses that may pose significant risks or affect radiation therapy. - Women who are pregnant, breastfeeding, or with plans for childbearing during the study. - Any other reasons deemed by the investigator to make the subject unsuitable for participation in the study. Always talk to your doctor about whether this trial is right for you.